Acadia Pharmaceuticals Pops And Drops

Acadia Pharmaceuticals Inc. ACAD shares were trading higher by $0.27 at $32.57 in Monday's session. Investors have decided to "sell the news" in the issue after the FDA recommenced approval of NUPLAZID.

After sprinting to $37 in after-hours trading upon the release of announcement, it quickly gave back those gains. By the open of the regular session, it was back to the $34 area and could only manage to make a high at $34.25 before sellers swarmed the issue.

So far, the ensuing decline has been taken beyond Friday's close, reaching $32.15, and is attempting to stage a rebound.